Holen Sie sich die Stockscreener-App
18.05
3.68%
0.64
Handel nachbörslich:
18.05
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$17.41
Offen:
$17.41
24-Stunden-Volumen:
1.65M
Relative Volume:
1.06
Marktkapitalisierung:
$1.61B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-3.967
EPS:
-4.55
Netto-Cashflow:
$-369.41M
1W Leistung:
+4.70%
1M Leistung:
+9.59%
6M Leistung:
-23.90%
1J Leistung:
+104.19%
1-Tages-Spanne:
$17.36
$18.09
1-Wochen-Bereich:
$15.60
$18.09
52-Wochen-Spanne:
$8.46
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
18.05 | 1.55B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics at Canaccord Genuity: Strategic Insights from Growth Conference - Investing.com Canada
Travere Therapeutics Receives Positive Growth Outlook from Analysts Amid Filspari's Promising Market Potential and Strategic Initiatives - AInvest
Trendlines Converge — Decision Point for Travere Therapeutics Inc.Earnings Performance Report & Entry Point Confirmation Alerts - beatles.ru
Ichimoku Cloud Indicates Uncertainty Around Travere Therapeutics Inc. [Weekly Risk Report]Free Verified Swing Trading Watchlist - 선데이타임즈
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2025 Earnings Call Transcript - MSN
Travere Therapeutics: Compelling FILSPARI Growth Is Hard To Ignore (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics (TVTX) Is Up 8.3% After Revenue Jump and Narrower Losses in Q2 – What's Changed - simplywall.st
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics price target raised to $34 from $32 at Citi - MSN
Healthcare Stocks Under the Spotlight: Eli Lilly & Co, Arrowhead Pharmaceuticals, and Travere Therapeutics - AInvest
Travere Therapeutics Reports Strong Q2 2025 Growth - MSN
Travere Therapeutics price target raised to $32 from $30 at Wedbush - Yahoo Finance
Travere Therapeutics Earnings Call Highlights FILSPARI Success - TipRanks
Travere Therapeutics shares fall 5.16% intraday despite positive earnings report and price target increase. - AInvest
Scotiabank Raises Price Target for Travere Therapeutics (TVTX) t - GuruFocus
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Path To Profitability - simplywall.st
Travere Therapeutics price target raised to $31 from $30 at Scotiabank - TipRanks
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty - Investing.com
Stifel lowers Travere Therapeutics stock price target to $20 on FSGS approval uncertainty By Investing.com - Investing.com South Africa
Wedbush Lifts Price Target on Travere Therapeutics to $32 From $30, Keeps Outperform Rating - MarketScreener
TVTX: Wedbush Raises Price Target and Maintains Outperform Ratin - GuruFocus
Travere: Q2 Earnings Snapshot - Huron Daily Tribune
Travere signals accelerating FILSPARI growth and prepares for FSGS launch while advancing REMS modifications - MSN
Earnings call transcript: Travere Therapeutics Q2 2025 beats revenue forecasts - Investing.com Canada
Travere Therapeutics Reports Second Quarter 2025 Financial Results - BioSpace
Travere Therapeutics: Scaling the Rare Disease Ladder—Can FILSPARI Sustain Its Momentum? - AInvest
Contradictions Unveiled: Travere Therapeutics' 2025Q2 Earnings Call Highlights Regulatory Challenges and Market Dynamics - AInvest
Transcript : Travere Therapeutics, Inc., Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Travere Therapeutics 2025 Q2 Earnings Strong Performance with 81.9% Net Loss Reduction - AInvest
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-Q Report - TradingView
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Travere Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Travere Therapeutics shares rise as Q2 results top expectations By Investing.com - Investing.com Australia
Travere Therapeutics shares rise as Q2 results top expectations - Investing.com India
Travere Therapeutics Inc Reports Q2 2025 Earnings: EPS Loss of $0.14 Beats Estimates, Revenue Surpasses Expectations at $114.4 Million - GuruFocus
Travere Therapeutics earnings beat by $0.16, revenue topped estimates - Investing.com Canada
Is Travere Therapeutics (NASDAQ:TVTX) Using Too Much Debt? - 富途牛牛
Travere Therapeutics to Participate at Upcoming Investor ConferencesAugust 5, 2025 - BioSpace
Earnings Preview: Travere Therapeutics - 富途牛牛
RBC to announce third quarter results on August 27, 2025 - The Globe and Mail
Trend Dashboard Flags Travere Therapeutics Inc. As Potential Swing TradeExpert Verified Stock Trade Ideas Backed by Data - metal.it
What are the technical indicators suggesting about Travere Therapeutics Inc.Achieve triple-digit returns with smart investing - Jammu Links News
Should I hold or sell Travere Therapeutics Inc. stock in 2025Grow your portfolio with growth-oriented stocks - Jammu Links News
How does Travere Therapeutics Inc. generate profit in a changing economyFree Investment Community - Jammu Links News
When is Travere Therapeutics Inc. stock expected to show significant growthDouble or triple returns - Jammu Links News
How many analysts rate Travere Therapeutics Inc. as a “Buy”Explosive capital gains - Jammu Links News
Is Travere Therapeutics Inc. a good long term investmentUnlock market-leading stock analysis - Jammu Links News
How does Travere Therapeutics Inc. compare to its industry peersExceptional trading performance - Jammu Links News
How strong is Travere Therapeutics Inc. company’s balance sheetPost Market Guidance With High Returns - jammulinksnews.com
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,784 |
37,553 |
93,126 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
May 05 '25 |
Sale |
21.05 |
18,924 |
398,350 |
419,173 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,771 |
37,280 |
128,215 |
| ROTE WILLIAM E. | Chief Research Officer |
May 05 '25 |
Sale |
21.05 |
3,198 |
67,318 |
100,241 |
| REED ELIZABETH E | Chief Legal Officer and GC |
May 05 '25 |
Sale |
21.05 |
4,920 |
103,566 |
89,482 |
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):